ONC

BeOne Medicines Ltd ADR

364.16

Aug 13 • 4:06 AM ET +5.11 (1.42%)

Healthcare Biotechnology Switzerland Large NASD

Peers: REGN VRTX ALNY ARGX BIIB AMGN BMRN GILD ABBV LLY

| Held by: IBB FBT CGGE CGIE BBH CGNG CANC EMEQ DFAE AVEM

Index	-
Market Cap	37.97B
Enterprise Value	34.76B
Income	657.23M
Sales	6.14B
Book/sh	45.78
Cash/sh	50.44
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	12000
IPO	Feb 03, 2016

P/E	64.00
Forward P/E	36.68
PEG	0.52
P/S	6.18
P/B	7.95
P/C	7.22
P/FCF	28.48
EV/EBITDA	32.16
EV/Sales	5.66
Quick Ratio	3.06
Current Ratio	3.40
Debt/Eq	0.40
LT Debt/Eq	0.34
Option/Short	Yes / Yes

EPS (ttm)	5.69
EPS next Y	9.93
EPS next Q	1.90
EPS this Y	174.95%
EPS next Y	37.30%
EPS next 5Y	70.73%
EPS past 3/5Y	- -
Sales past 3/5Y	55.88% 76.88%
EPS Y/Y TTM	449.53%
Sales Y/Y TTM	34.39%
EPS Q/Q	143.77%
Sales Q/Q	29.39%
Earnings	Aug 05 BMO
EPS/Sales Surpr.	23.45% 4.95%

Insider Own	0.52%
Insider Trans	-63.61%
Inst Own	33.14%
Inst Trans	-0.79%
ROA	8.49%
ROE	14.70%
ROIC	9.50%
Gross Margin	86.76%
Oper. Margin	15.06%
Profit Margin	10.70%
SMA20	10.03%
SMA50	20.22%
SMA200	15.52%
Trades

Shs Outstand	104.17M
Shs Float	103.73M
Short Float	0.85%
Short Ratio	2.61
Short Interest	0.88M
52W High	385.22 -5.47%
52W Low	253.95 43.40%
Volatility	2.43% 2.55%
ATR (14)	9.47
RSI (14)	78.36
Beta	0.52
Rel Volume	0.11
Avg Volume	337.23K
Volume	1,887

Perf Week	10.42%
Perf Month	17.00%
Perf Quarter	15.04%
Perf Half Y	3.67%
Perf YTD	19.86%
Perf Year	18.42%
Perf 3Y	84.22%
Perf 5Y	31.85%
Perf 10Y	1193.64%
Recom	1.16
Target Price	434.65
Prev Close	359.05
Price	364.16
Change %	1.42%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-13-26	Upgrade	Jefferies	Hold → Buy	$380
Mar-27-26	Initiated	Wolfe Research	Outperform	$340
Mar-16-26	Downgrade	Jefferies	Buy → Hold	$290
Nov-24-25	Initiated	Truist	Buy
Sep-18-25	Initiated	Barclays	Overweight	$385
Apr-07-25	Initiated	RBC Capital Mkts	Outperform	$312
Mar-03-25	Upgrade	BofA Securities	Neutral → Buy	$207 → $320
Dec-03-24	Resumed	Morgan Stanley	Overweight	$300
Sep-18-24	Initiated	JMP Securities	Mkt Outperform	$288
Feb-06-24	Resumed	JP Morgan	Overweight	$185
Sep-12-23	Initiated	Macquarie	Outperform	$259
Aug-17-23	Initiated	Jefferies	Buy	$287
Jul-17-23	Initiated	Citigroup	Buy	$275
Jun-30-23	Downgrade	Bernstein	Outperform → Mkt Perform	$335 → $196
Jan-12-23	Initiated	Daiwa Securities	Buy	$308
Oct-13-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$177 → $200
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$205
Aug-09-22	Resumed	JP Morgan	Overweight	$296
Mar-17-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$300 → $177
Feb-07-22	Initiated	Deutsche Bank	Buy

Show Previous Ratings

Aug-12-26 09:04PM	BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ... (GuruFocus.com)
Jul-23-26 08:41AM	BeOne Medicines expands New Jersey campus with additional $300 million investment (NASDAQ:ONC) (InvestorsHub)
06:00AM	BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines (Business Wire)
Jun-30-26 06:00AM	BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma (Business Wire)
Jun-11-26 07:24AM	BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit (Business Wire)
06:00AM	Loading…
Jun-01-26 06:00AM	BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026 (Business Wire)
May-29-26 06:00AM	BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026 (Business Wire)
May-27-26 05:00PM	BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026 (Business Wire)
May-26-26 06:01AM	BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (Business Wire)
May-21-26 06:00AM	BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts (Business Wire)
May-13-26 01:27PM	BeOne Medicines BEQALZI (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma (Business Wire)
May-06-26 06:00AM	BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates (Business Wire) +5.32%
May-04-26 09:43AM	AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls (The Fly)
Apr-29-26 06:00AM	U.S. FDA Grants Priority Review to BeOne Medicines TEVIMBRA in First-Line HER2+ GEA (Business Wire)
Apr-22-26 06:01AM	BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6 (Business Wire)
08:02PM	Loading…
Mar-03-26 08:02PM	BeOne Medicines Ltd (ONC) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Expansion (GuruFocus.com) -5.51%
Mar-01-26 09:59AM	BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment (Insider Monkey)
Feb-26-26 09:30AM	Here's What Key Metrics Tell Us About BeOne Medicines Ltd. - Sponsored ADR (ONC) Q4 Earnings (Zacks) -8.48%
06:00AM	BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership (Business Wire)
Feb-17-26 06:00AM	BeOne Medicines to Present at Upcoming Investor Conferences (Business Wire)
Feb-13-26 05:19AM	Bernstein Remains a Buy on BeOne Medicines AG (ONC) (Insider Monkey)
Feb-11-26 06:00AM	BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26 (Business Wire)
Feb-02-26 03:10AM	3 Stocks to Buy in February (Motley Fool)
Jan-31-26 09:36AM	Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development (Insider Monkey)
Jan-30-26 02:07AM	Citizens Highlights BeOne Medicines' (ONC) $3.8B Revenue Potential for 2025 (Insider Monkey)
Jan-29-26 12:28PM	FDA Accepts Summit's Lung Cancer Drug Application, Review Underway (Benzinga)
Jan-13-26 06:00AM	BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +5.11%
Jan-07-26 10:22AM	Is the Options Market Predicting a Spike in BeOne Medicines Stock? (Zacks)
Jan-06-26 01:30PM	ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA (Business Wire)
Dec-31-25 08:51AM	Strong Momentum Lifted BeOne Medicines AG (ONC) in Q3 (Insider Monkey)
06:01AM	Loading…
Dec-23-25 06:01AM	BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-25 06:00AM	BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma (Business Wire)
Dec-14-25 03:30AM	Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. (Barrons.com)
Dec-08-25 08:00AM	BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Nave Chronic Lymphocytic Leukemia (Business Wire)
Dec-07-25 06:00PM	Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies (Business Wire)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-26-25 04:11PM	Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied (Investor's Business Daily)
Nov-21-25 12:59PM	This Pharma Stock Owned By Top Fund Flirts With Entry As Earnings Surge 452% (Investor's Business Daily)
Nov-20-25 06:00AM	BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025 (Business Wire)
Nov-17-25 08:10AM	Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar. (Barrons.com)
06:00AM	Positive Phase 3 Results Support ZIIHERA as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (Business Wire)
Nov-12-25 04:39PM	Stock Market Today: Dow Hits New Highs; Lilly, Barrick, Goldman Break Out (Live Coverage) (Investor's Business Daily) +9.84%
04:30PM	BeOne, IBD Stock Of The Day, Breaks Out As It Takes On Cancer Giants J&J, AbbVie (Investor's Business Daily)
01:19PM	BeOne Medicines Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
12:55PM	IBD Stock Of The Day BeOne Breaks Out As It Takes On Cancer Giants J&J, AbbVie (Investor's Business Daily)
10:31AM	Stock Market Today: Dow Rises But Nasdaq Cools Again As Nvidia, AMD Rally (Live Coverage) (Investor's Business Daily)
Nov-11-25 12:07PM	Biotech Leader BeOne Medicines Eyes New Buy Point As Cancer Drug Sales Surge (Investor's Business Daily)
Nov-10-25 08:03PM	BeOne Medicines Ltd (ONC) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Nov-06-25 11:30AM	BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:00AM	BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates (Business Wire)
Oct-28-25 06:01AM	BeOne Medicines to Present at Upcoming Investor Conferences (Business Wire)
Oct-21-25 01:41PM	SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments (Zacks)
Oct-20-25 06:00AM	BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025 (Business Wire)
Oct-13-25 06:00AM	BeOne Medicines Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA (Business Wire)
Oct-03-25 04:21PM	How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment (Investor's Business Daily)
Oct-02-25 01:35AM	BeOne Medicines (ONC) Gains Barclays Overweight Rating Ahead of Key 2025 Data Readouts (Insider Monkey)
Sep-29-25 10:35AM	Here's Why BeOne Medicines Ltd. (ONC) Declined in Q2 (Insider Monkey)
Sep-18-25 03:00AM	China's Young Consumers Set the Global Trend. What They're Buying Now. (Barrons.com)
Sep-14-25 01:16AM	Citizens JMP Maintains a Buy Rating on BeOne Medicines (ONC) (Insider Monkey)
Sep-12-25 01:01AM	BeOne Medicines (ONC) Reports Positive Phase 1/2 Results for Sonrotoclax in MCL (Insider Monkey)
Sep-10-25 03:55PM	China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order (Investor's Business Daily) -10.59%
Aug-29-25 06:00AM	BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL) (Business Wire)
Aug-28-25 04:55AM	BeOne Medicines Ltd. (ONC) Unveils Promising Breast Cancer Therapies at ASCO 2025 (Insider Monkey)
Aug-27-25 06:00AM	European Commission Approves TEVIMBRA as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025 (Business Wire)
Aug-26-25 06:01AM	BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
Aug-21-25 06:00AM	European Commission Approves Tablet Formulation of BeOne Medicines BRUKINSA for All Approved Indications (Business Wire)
Aug-15-25 12:55PM	This Medical Stock With Blockbuster Cancer Drug Clears Entry Amid 923% Earnings Growth (Investor's Business Daily)
10:04AM	This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine (Investor's Business Daily)
Aug-08-25 12:44PM	Hims Stock Gets Booted Off IBD 50 While Other Volatile Names Hang On (Investor's Business Daily)
Aug-06-25 11:30AM	BeOne Medicines Ltd. - Sponsored ADR (ONC) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
06:00AM	BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates (Business Wire)
Jul-31-25 06:00AM	BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstroms Macroglobulinemia (Business Wire)
Jul-28-25 06:00AM	BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA in Neoadjuvant/Adjuvant NSCLC Treatment (Business Wire)
Jul-25-25 10:44PM	BeOne Medicines Ltd. (ONC) Wins EU Nod for Tevimbra (Insider Monkey)
10:06AM	Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock? (Zacks)
Jul-18-25 03:43PM	The S&P 500 and Nasdaq Are Joined By These Stocks Hitting New Highs (Investor's Business Daily)
10:06AM	BeOne Medicines Ltd. - Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains? (Zacks)
Jul-16-25 12:58PM	Looming Tariffs Don't Scare This Swiss Cancer Treatment Stock (Investor's Business Daily)
06:00AM	BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6 (Business Wire)
Jul-10-25 06:00AM	European Commission Approves TEVIMBRA in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma (Business Wire)
Jun-28-25 08:35AM	BeOne Medicines price target raised to $330 from $313 at Morgan Stanley (TipRanks)
Jun-26-25 06:00AM	BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day (Business Wire)
Jun-25-25 06:00AM	BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA (Business Wire)
Jun-12-25 06:00AM	BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025 (Business Wire) +5.38%
Jun-11-25 04:05PM	U.S. FDA Approves Tablet Formulation of BeOnes BRUKINSA for All Approved Indications (Business Wire)
06:01AM	BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025 (Business Wire)
Jun-05-25 02:03PM	Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple (Investor's Business Daily)
Jun-02-25 06:00AM	BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025 (Business Wire)
May-31-25 08:00AM	BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSAs Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025 (Business Wire)
May-27-25 08:30AM	BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology (Business Wire)
06:00AM	BeiGene Receives Positive CHMP Opinion for TEVIMBRA as a First-Line Treatment for Nasopharyngeal Cancer (Business Wire)
May-22-25 06:00AM	BeiGene Presents Pioneering Cancer Research at ASCO 2025 Redefining Treatment Across Hematology and Solid Tumors (Business Wire)
May-14-25 04:05PM	BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSAs Leadership and Next-Generation Innovation (Business Wire)
May-13-25 06:01AM	BeiGene to Present at the RBC Capital Markets Global Healthcare Conference (Business Wire)
May-12-25 07:33AM	Trumps Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks (The Wall Street Journal)
12:05AM	Trump Drug Plan Hits Pharma Stocks (The Wall Street Journal)
12:05AM	Trump Drug Plan Hits Asian Pharma Stocks (The Wall Street Journal)
May-09-25 07:52AM	BeiGene, Ltd. (ONC): Among Billionaire Lei Zhang's Stock Picks with Huge Upside Potential (Insider Monkey)
May-08-25 01:00PM	BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ... (GuruFocus.com)
May-07-25 02:05PM	BeiGene targets $4.9B-$5.3B revenue for 2025 with strong BRUKINSA and pipeline growth (Seeking Alpha)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Co-FounderMr. John V. Oyler

President and Global Head of Research & DevelopmentMr. Wang Lai Ph.D.

Co-Chairman of Scientific Advisory BoardDr. Xiaodong Wang Ph.D.

Chief Financial OfficerMr. Aaron Rosenberg

General CounselMr. Chan Lee

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
OYLER JOHN	Chief Executive Officer	Aug 10 '26	Sale	357.87	115,011	41,159,461	125,799	Aug 12 05:53 PM
OYLER JOHN	Chief Executive Officer	Aug 11 '26	Sale	361.90	70,907	25,661,417	54,892	Aug 12 05:53 PM
OYLER JOHN	Chief Executive Officer	Aug 12 '26	Sale	358.15	54,892	19,659,594	0	Aug 12 05:53 PM
CHAN LEE	Officer	Aug 11 '26	Proposed Sale	359.00	2,002	718,718		Aug 11 04:31 PM
JOHN V OYLER	Director	Aug 10 '26	Proposed Sale	348.27	240,810	83,866,899		Aug 10 04:36 PM
Rosenberg Aaron	Chief Financial Officer	Aug 03 '26	Sale	312.71	1,157	361,811	0	Aug 05 05:15 PM
Lee Chan Henry	SVP, General Counsel	Jul 30 '26	Sale	323.69	1,044	337,932	0	Aug 03 05:18 PM
AARON ROSENBERG	Officer	Aug 03 '26	Proposed Sale	312.72	1,157	361,811		Aug 03 04:50 PM
CHAN LEE	Officer	Jul 30 '26	Proposed Sale	323.69	1,044	337,932		Jul 30 05:34 PM
Lee Chan Henry	SVP, General Counsel	Jul 22 '26	Option Exercise	191.58	1,669	319,740	1,669	Jul 24 04:51 PM
Lee Chan Henry	SVP, General Counsel	Jul 22 '26	Sale	325.00	1,669	542,425	0	Jul 24 04:51 PM
OYLER JOHN	Chief Executive Officer	Jul 20 '26	Option Exercise	119.96	33,990	4,077,440	33,990	Jul 22 05:03 PM
OYLER JOHN	Chief Executive Officer	Jul 21 '26	Sale	317.67	61,397	19,504,058	0	Jul 22 05:03 PM
OYLER JOHN	Chief Executive Officer	Jul 20 '26	Sale	312.25	48,316	15,086,797	0	Jul 22 05:03 PM
CHAN LEE	Officer	Jul 22 '26	Proposed Sale	318.69	2,001	637,689		Jul 22 04:29 PM
OYLER JOHN	Chief Executive Officer	Jul 17 '26	Option Exercise	119.96	64,628	7,752,775	64,628	Jul 17 05:36 PM
OYLER JOHN	Chief Executive Officer	Jul 17 '26	Sale	312.00	64,628	20,163,907	0	Jul 17 05:36 PM
OYLER JOHN	Chief Executive Officer	Jul 16 '26	Option Exercise	143.38	166,597	23,887,477	166,597	Jul 17 05:31 PM
OYLER JOHN	Chief Executive Officer	Jul 15 '26	Option Exercise	148.00	116,557	17,250,520	116,557	Jul 17 05:31 PM
OYLER JOHN	Chief Executive Officer	Jul 16 '26	Sale	318.09	166,597	52,992,224	0	Jul 17 05:31 PM
OYLER JOHN	Chief Executive Officer	Jul 15 '26	Sale	311.95	116,557	36,359,374	0	Jul 17 05:31 PM
OYLER JOHN	Chief Executive Officer	Jul 14 '26	Option Exercise	54.06	133,600	7,222,959	133,600	Jul 14 09:26 PM
OYLER JOHN	Chief Executive Officer	Jul 14 '26	Sale	305.95	145,861	44,626,424	0	Jul 14 09:26 PM
OYLER JOHN	Chief Executive Officer	Jul 13 '26	Option Exercise	36.90	48,520	1,790,388	48,520	Jul 14 09:25 PM
OYLER JOHN	Chief Executive Officer	Jul 10 '26	Option Exercise	36.90	11,698	431,656	11,698	Jul 14 09:25 PM
OYLER JOHN	Chief Executive Officer	Jul 13 '26	Sale	304.35	48,520	14,766,883	0	Jul 14 09:25 PM
OYLER JOHN	Chief Executive Officer	Jul 10 '26	Sale	298.34	11,698	3,489,925	0	Jul 14 09:25 PM
JOHN V OYLER	Director	Jul 14 '26	Proposed Sale	303.96	513,574	156,105,953		Jul 14 04:48 PM
Lee Chan Henry	SVP, General Counsel	Jul 08 '26	Option Exercise	191.56	664	127,196	664	Jul 10 04:44 PM
Lee Chan Henry	SVP, General Counsel	Jul 08 '26	Sale	302.46	664	200,833	0	Jul 10 04:44 PM
JOHN V OYLER	Director	Jul 10 '26	Proposed Sale	302.83	150,000	45,424,500		Jul 10 04:36 PM
PAN-OYLER FOUNDATION	Director	Jul 10 '26	Proposed Sale	302.83	49,541	15,002,501		Jul 10 04:35 PM
Wu Xiaobin	President and COO	Jun 23 '26	Sale	276.26	1,292	356,927	0	Jun 25 05:15 PM
OYLER JOHN	Chief Executive Officer	Jun 23 '26	Sale	273.78	3,410	933,592	0	Jun 25 05:15 PM
Wang Lai	President, Global Head of R&D	Jun 23 '26	Sale	276.74	1,068	295,553	0	Jun 25 05:14 PM
LAI WANG	Officer	Jun 23 '26	Proposed Sale	276.73	1,068	295,553		Jun 23 04:24 PM
XIAOBIN WU	Officer	Jun 23 '26	Proposed Sale	276.26	1,292	356,927		Jun 23 04:21 PM
JOHN OYLER	Officer	Jun 23 '26	Proposed Sale	273.78	3,410	933,592		Jun 23 04:13 PM
Wu Xiaobin	President and COO	Jun 16 '26	Sale	266.76	1,357	361,997	0	Jun 18 05:19 PM
OYLER JOHN	Chief Executive Officer	Jun 16 '26	Sale	265.55	3,693	980,686	0	Jun 18 05:19 PM
Lee Chan Henry	SVP, General Counsel	Jun 16 '26	Sale	265.98	590	156,925	0	Jun 18 05:19 PM
Wang Lai	President, Global Head of R&D	Jun 16 '26	Sale	265.39	1,169	310,236	0	Jun 18 05:19 PM
CHAN LEE	Officer	Jun 16 '26	Proposed Sale	265.98	590	156,925		Jun 16 04:15 PM
LAI WANG	Officer	Jun 16 '26	Proposed Sale	265.39	1,169	310,236		Jun 16 04:14 PM
XIAOBIN WU	Officer	Jun 16 '26	Proposed Sale	266.76	1,357	361,997		Jun 16 04:12 PM
JOHN OYLER	Officer	Jun 16 '26	Proposed Sale	265.55	3,693	980,686		Jun 16 04:11 PM
Ball Titus B.	Principal Accounting Officer	Jun 11 '26	Sale	257.20	169	43,467	0	Jun 15 05:55 PM
Wang Lai	President, Global Head of R&D	Jun 11 '26	Sale	261.00	756	197,318	0	Jun 15 05:55 PM
Rosenberg Aaron	Chief Financial Officer	Jun 11 '26	Sale	257.74	631	162,637	0	Jun 15 05:55 PM
Wu Xiaobin	President and COO	Jun 11 '26	Sale	261.20	626	163,512	0	Jun 15 05:55 PM
Lee Chan Henry	SVP, General Counsel	Jun 11 '26	Sale	257.63	428	110,268	0	Jun 15 05:55 PM
OYLER JOHN	Chief Executive Officer	Jun 11 '26	Sale	257.24	1,949	501,355	0	Jun 15 05:55 PM
CORAZON D. SANDERS	Director	Jun 15 '26	Proposed Sale	265.50	945	250,894		Jun 15 04:21 PM
XIAOBIN WU	Officer	Jun 11 '26	Proposed Sale	261.20	626	163,512		Jun 11 04:32 PM
LAI WANG	Officer	Jun 11 '26	Proposed Sale	261.41	756	197,630		Jun 11 04:29 PM
AARON ROSENBERG	Officer	Jun 11 '26	Proposed Sale	257.74	631	162,637		Jun 11 04:25 PM
TITUS BENJAMIN BALL	Officer	Jun 11 '26	Proposed Sale	257.20	169	43,467		Jun 11 04:24 PM
CHAN LEE	Officer	Jun 11 '26	Proposed Sale	257.63	428	110,268		Jun 11 04:23 PM
JOHN OYLER	Officer	Jun 11 '26	Proposed Sale	257.24	1,949	501,355		Jun 11 04:23 PM
Ball Titus B.	Principal Accounting Officer	Jun 08 '26	Sale	271.33	136	36,901	0	Jun 10 05:27 PM
Lee Chan Henry	SVP, General Counsel	Jun 08 '26	Sale	270.42	871	235,539	0	Jun 10 05:26 PM
Wang Lai	President, Global Head of R&D	Jun 08 '26	Sale	269.38	1,367	368,247	0	Jun 10 05:25 PM
Wu Xiaobin	President and COO	Jun 08 '26	Sale	269.37	1,484	399,738	0	Jun 10 05:23 PM
OYLER JOHN	Chief Executive Officer	Jun 08 '26	Sale	270.56	4,940	1,336,548	0	Jun 10 05:22 PM
TITUS BENJAMIN BALL	Officer	Jun 08 '26	Proposed Sale	271.33	136	36,901		Jun 08 04:31 PM
CHAN LEE	Officer	Jun 08 '26	Proposed Sale	270.42	871	235,539		Jun 08 04:29 PM
LAI WANG	Officer	Jun 08 '26	Proposed Sale	269.38	1,367	368,247		Jun 08 04:28 PM
XIAOBIN WU	Officer	Jun 08 '26	Proposed Sale	269.37	1,484	399,738		Jun 08 04:23 PM
JOHN OYLER	Officer	Jun 08 '26	Proposed Sale	270.56	4,940	1,336,548		Jun 08 04:18 PM
Yi Qingqing	Director	Jun 01 '26	Sale	279.13	235	65,596	0	Jun 03 04:10 PM
QINGQING YI	Director	Jun 01 '26	Proposed Sale	279.13	235	65,596		Jun 01 04:27 PM
Riva Alessandro	Director	May 22 '26	Sale	309.51	212	65,617	0	May 27 05:29 PM
Dugan Margaret	Director	May 22 '26	Sale	309.60	212	65,636	0	May 27 05:26 PM
Sanders Corazon (Corsee) D.	Director	May 22 '26	Sale	309.59	212	65,633	0	May 27 05:26 PM
BAKER BROS. ADVISORS LP	Director	May 22 '26	Sale	23.82	10,998	261,981	142,566	May 27 04:54 PM
MICHAEL GOLLER	Director	May 22 '26	Proposed Sale	310.07	211	65,424		May 22 04:28 PM
RANJEEV KRISHANA	Director	May 22 '26	Proposed Sale	309.28	212	65,567		May 22 04:25 PM
ALESSANDRO RIVA	Director	May 22 '26	Proposed Sale	309.51	212	65,617		May 22 04:22 PM
MARGARET DUGAN	Director	May 22 '26	Proposed Sale	309.60	212	65,636		May 22 04:20 PM
CORAZON D. SANDERS	Director	May 22 '26	Proposed Sale	309.59	212	65,633		May 22 04:18 PM
Lee Chan Henry	SVP, General Counsel	May 13 '26	Option Exercise	191.56	332	63,598	332	May 15 04:39 PM
Lee Chan Henry	SVP, General Counsel	May 13 '26	Sale	310.72	332	103,159	0	May 15 04:39 PM
CHAN LEE	Officer	May 13 '26	Proposed Sale	315.07	1,328	418,413		May 13 04:27 PM
Lee Chan Henry	SVP, General Counsel	Apr 08 '26	Option Exercise	191.56	332	63,598	332	Apr 10 05:40 PM
Lee Chan Henry	SVP, General Counsel	Apr 08 '26	Sale	311.59	332	103,448	0	Apr 10 05:40 PM
Lee Chan Henry	SVP, General Counsel	Mar 11 '26	Option Exercise	191.64	341	65,348	341	Mar 13 05:26 PM
Lee Chan Henry	SVP, General Counsel	Mar 11 '26	Sale	300.00	341	102,300	0	Mar 13 05:26 PM
Lee Chan Henry	SVP, General Counsel	Feb 04 '26	Option Exercise	191.40	1,660	317,721	1,660	Feb 06 04:57 PM
Lee Chan Henry	SVP, General Counsel	Feb 04 '26	Sale	349.52	1,660	580,197	0	Feb 06 04:57 PM
CHAN LEE	Officer	Feb 04 '26	Proposed Sale	346.38	4,676	1,619,673		Feb 04 04:21 PM
Lee Chan Henry	SVP, General Counsel	Jan 07 '26	Option Exercise	191.56	664	127,196	664	Jan 09 05:15 PM
Lee Chan Henry	SVP, General Counsel	Jan 07 '26	Sale	331.76	664	220,289	0	Jan 09 05:15 PM
OYLER JOHN	Chief Executive Officer	Dec 15 '25	Sale	307.79	75,631	23,278,679	24,369	Dec 17 04:47 PM
OYLER JOHN	Chief Executive Officer	Dec 16 '25	Sale	302.87	24,369	7,380,739	0	Dec 17 04:47 PM
JOHN V OYLER	Director	Dec 15 '25	Proposed Sale	319.06	100,000	31,906,000		Dec 15 04:32 PM
Lee Chan Henry	SVP, General Counsel	Dec 10 '25	Option Exercise	191.56	332	63,598	332	Dec 12 04:56 PM
Lee Chan Henry	SVP, General Counsel	Dec 11 '25	Option Exercise	191.56	332	63,598	332	Dec 12 04:56 PM
Lee Chan Henry	SVP, General Counsel	Dec 11 '25	Sale	325.00	332	107,900	0	Dec 12 04:56 PM
Lee Chan Henry	SVP, General Counsel	Dec 10 '25	Sale	318.28	332	105,669	0	Dec 12 04:56 PM
Sanders Corazon (Corsee) D.	Director	Nov 26 '25	Option Exercise	159.03	2,627	417,772	2,627	Dec 01 04:57 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ONC

BeOne Medicines Ltd ADR

Upgrade your Finviz experience